A randomised controlled trial testing the rebound‐preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis-Reference-Cited by-同舟云学术

A randomised controlled trial testing the rebound‐preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis

Published:2022-11-04 Issue:2 Volume:34 Page:99-106
ISSN:0959-4493
Container-title:Veterinary Dermatology
language:en
Short-container-title:Veterinary Dermatology

Author:

Olivry Thierry¹^ORCID,Lokianskiene Viktorija²,Blanco Alejandro³,Mestre Pablo Del⁴,Bergvall Kerstin⁵^ORCID,Beco Luc⁶

Affiliation:

1. Department of Clinical Sciences, College of Veterinary Medicine NC State University Raleigh North Carolina USA

2. VetPet LT Jonava Lithuania

3. Clínica Dermatológica San Antonio de Padua Provincia de Buenos Aires Argentina

4. Consultorio Dermatológico Veterinario Mar del Plata Argentina

5. Faculty of Veterinary Medicine and Animal Husbandry Swedish University of Agricultural Sciences Uppsala Sweden

6. Cabinet Vétérinaire Spa Belgium

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

General Veterinary

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/vde.13134

Reference19 articles.

1. Oclacitinib ( APOQUEL ® ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

2. A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the J anus kinase inhibitor oclacitinib ( A poquel ® ) in client‐owned dogs with atopic dermatitis

3. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client‐owned dogs

4. Efficacy of oclacitinib (Apoquel ® ) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client‐owned dogs in Australia

5. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate (OKV‐1001): A pilot open‐label, single‐arm multicentric clinical trial;Veterinary Dermatology;2024-08-12

2. A randomized double-blind clinical trial: Comparison of oclacitinib with a traditional Chinese herbal medicine product (Dihuang Guiqin capsule) in the treatment of canine atopic dermatitis;Research in Veterinary Science;2024-05

3. A Randomized Controlled Trial to Evaluate the Impact of a Novel Probiotic and Nutraceutical Supplement on Pruritic Dermatitis and the Gut Microbiota in Privately Owned Dogs;Animals;2024-01-30

4. Investigation of the effects of oclacitinib maleate on clinical improvement and serum cytokine levels in dogs with atopic dermatitis;Medycyna Weterynaryjna;2024